Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

NCT05555823 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ATR-002
DRUG: Placebo
DRUG: Repaglinide
DRUG: Celecoxib

Sponsor

Atriva Therapeutics GmbH